Is there a generic for Ergoloid mesylates?

Yes. The FDA Orange Book lists 30 approved generic (ANDA) applications for Ergoloid mesylates, referencing the brand HYDERGINE. Generics rated with an "A" therapeutic-equivalence code are considered substitutable for the brand.

What is the reference-listed drug for Ergoloid mesylates?

HYDERGINE (NDA 017993, NOVARTIS) is the reference-listed drug — the approved product a generic applicant must show its version is the same as.

What dosage forms of Ergoloid mesylates are approved?

Ergoloid mesylates is approved in the following dosage forms: capsule, solution, tablet.

FDA Orange Book · active-ingredient family

Ergoloid mesylates

Ergoloid mesylates: 4 brands, 30 generics; first approved May 27, 1982; generic available.

Generic availableHas discontinued products

Generic status & protection

Generic available — 30 ANDA applications approved.

Brands (NDA)

Generics (ANDA)

Listed patents

Presentations

Originator applications

Brand (NDA) products

HYDERGINERLD

NOVARTISNDA 017993—2 strengths

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET	ORAL	Discontinued	—
0.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET	ORAL	Discontinued	—

HYDERGINE LC

NOVARTISNDA 0187061983

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	CAPSULE	ORAL	Discontinued	—

HYDERGINE

NOVARTISNDA 018418—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG/ML	SOLUTION	ORAL	Discontinued	—

HYDERGINE

NOVARTISNDA 009087—2 strengths

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	SUBLINGUAL	Discontinued	—
0.5MG	TABLET	SUBLINGUAL	Discontinued	—

Abbreviated applications

Generic (ANDA) products (30)

ERGOLOID MESYLATES

SUN PHARM INDUSTRIESANDA 0811131991

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	ORAL	Discontinued	—

ERGOLOID MESYLATES

SUPERPHARMANDA 0892331986

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.5MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

SUPERPHARMANDA 0892341986

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

MUTUAL PHARMANDA 0888911985

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	ORAL	Discontinued	—

GERIMAL

WATSON LABSANDA 0882071984

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	ORAL	Discontinued	—

ERGOLOID MESYLATES

VANGARDANDA 0880131982

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.5MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

VANGARDANDA 0880141982

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

WATSON LABSANDA 0872441982

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	ORAL	Discontinued	—

ERGOLOID MESYLATES

WATSON LABSANDA 0864331982

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	ORAL	Discontinued	—

ALKERGOT

SANDOZANDA 085153—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.5MG	TABLET	SUBLINGUAL	Discontinued	—

ALKERGOT

SANDOZANDA 087417—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	SUBLINGUAL	Discontinued	—

CIRCANOL

3MANDA 084868—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.5MG	TABLET	SUBLINGUAL	Discontinued	—

CIRCANOL

3MANDA 085809—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	SUBLINGUAL	Discontinued	—

DEAPRIL-ST

BRISTOL MYERS SQUIBBANDA 085020—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

KV PHARMANDA 085899—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.5MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

KV PHARMANDA 086265—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.5MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

KV PHARMANDA 085900—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

KV PHARMANDA 086264—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

LEDERLEANDA 086984—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.5MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

LEDERLEANDA 086985—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

SUN PHARM INDUSTRIESANDA 087407—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.5MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

SUN PHARM INDUSTRIESANDA 087552—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

WATSON LABSANDA 084930—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.5MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

WATSON LABSANDA 087233—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.5MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

WATSON LABSANDA 085177—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	SUBLINGUAL	Discontinued	—

ERGOLOID MESYLATES

WATSON LABSANDA 087183—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	SUBLINGUAL	Discontinued	—

GERIMAL

WATSON LABSANDA 086189—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.5MG	TABLET	SUBLINGUAL	Discontinued	—

GERIMAL

WATSON LABSANDA 086188—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	SUBLINGUAL	Discontinued	—

HYDROGENATED ERGOT ALKALOIDS

IVAX PHARMSANDA 087186—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.5MG	TABLET	SUBLINGUAL	Discontinued	—

HYDROGENATED ERGOT ALKALOIDS

IVAX PHARMSANDA 087185—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1MG	TABLET	SUBLINGUAL	Discontinued	—

Orange Book patent file

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

FDA approval span

Approval history

First approval

May 27, 1982

44 yr 9 mo ago

Most recent approval

Oct 31, 1991

35 yr 2 mo ago

Approvals span 1982–1991 across 34 FDA applications.

Brand (NDA) 412%

Generic (ANDA) 3088%

Ergoloid mesylates — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo